Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ivan...chill. The 12 week data = 104 weeks of trial extension. You don't extend a 32pt P2 by two years unless there is a very, VERY good reason. Smart move by Missling to leave the 12 week enigma behind and show tangible results...patients continuing the therapy after 1 year.
Did the smart traders sell @ 5.50 to reload @ 4.80 tomorrow? Or wait for open @ 5.30 and cruise to 5.65? Hoping for one or the other and you are playing checkers. Be prepared for both and you are playing chess.
ClosetInvestor: Does it matter? 2 year extension. DBPCR phase study in the works. Independent clinical testing in additional indications. Top-tier SAB participating enthusiastically. Young, bright, goal-oriented management.
Personally, I don't need any more info on A2-73. My wife is pregnant with A3-71 and it's going to be beautiful!
§
The pessimist in me wants to say, "trial participants always want extensions" but I am not finding much evidence that that is the case. Adverse Event info will be very important I would say, in an extension of this magnitude. If the drug proves completely safe, and the general health of participants starts to improve along with an absence of even non-study related AE withdrawals, the FDA will take notice.
I would trade a pound of pps gain for an ounce of safe investment appearance any day!
Go Anavex!
§
I would say since it is open label that this describes a comparison of the patients who were already taking donepezil (24 I believe) with those (6) who did not receive donepezil as part of the therapy. The trend continued positive after the time period in which the patients in the previous 24 week donepezil trial showed decline...6 to 8 weeks.
Meaning A2-73 works beyond it's synergy with donepezil.
If the company is willing to fund another TWO YEAR extension to a P2a trial management must not be concerned with the funding. Hint-hint
Holding even on an awful day in the sector. That'll do pig!
§
It will be in there. No need to draw attention beforehand.
This is encouraging:
"A minimum dose of 14 mg of ANAVEX 2-73 seem to be required to achieve a therapeutic effect and to keep MMSE score unchanged."
14mg keeps MMSE unchanged?
Don't forget the A3-71 poster goes on display today too. hopefully a pdf will come available for that.
The company would not have submitted for a two year extension if the findings were not absolutely significant. frrol's wish-granting is outstanding news!
It also appears to be a new trial? Different endpoints? Thoughts?
"The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks..."
§
Yes, frrol made the call. The drug is obviously working. Congrats team. Let's hope the gap holds.
§
Sounds like a certain CEO I know! Thanks for the props. Good MBs are indispensable for the little guys.
scottsmith: Apparently their NFLX adventure made them bold in their old age!
§
Well put. $8 is an extremely rich valuation for us at this point and holding any level up there would be outstanding.
§
My relatives who went all-in @ 3.60 informed me that they went out today enough to pay off their mortgage after taxes. Bravo folks!
They will attempt to swing what is left and tackle undesired employment next. Good luck!
Losses for the last two months have been paired. 5.20 a crucial support area.
Knock it off. Old data.
ADCD-ADL will be +3.5 and MMSE +7 for the cohort. But soft bash if you must
Followers: 558
See, they're still here!
§
You have the biggest pom-poms on the squad, you silly goof!
Thing is if you end-up being right, it's the last thing you need to be right about. Woot-woot!
Do mixed sigma-1/M receptor ligands offer neuroprotection or just make the person feel better?
Hippies don't get Alzheimers. Why?
http://www.ghalabs.com/2015/10/23/hippies-dont-get-alzheimers/
Ligands man...ligands! Especially bicyclic heterocyclic spiro compounds.
All one light.
§
Identifying Future Exponential Growth in Biotech
Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical-stage biopharmaceutical company that focuses on therapies for Alzheimer's Disease, has encouraged investors with the company's preclinical results of its ANAVEX 2-73 in an exploratory study in a Rett syndrome model.
"The data demonstrates dose related and significant improvements in an array of behavioral and gait paradigms in a mouse model with a MECP2-null mutation that causes neurological symptoms that mimic Rett syndrome. There is a tremendous need for therapeutic solutions for the individuals living with Rett syndrome and their families, and we are very encouraged by the data we have seen with ANAVEX 2-73," said Steven Kaminsky, PhD, Chief Science Officer of Rettsyndrome.org.
http://finance.yahoo.com/news/identifying-future-exponential-growth-biotech-140000542.html
§
I don't know. Perhaps he is trying to secure a patent on his own. I think the original Greek COM patent expires late next year. So maybe his agreement with Anavex also expires with that patent and he is trying to get a PLUS patent to renegotiate that agreement...or sell it to someone else. That is doubtful. It would not make sense for him to try and take it to another company for development. He is 73 and as a scientist, his overwhelmingly predominant goal would be to see the compound approved and in use. He agreed to let Anavex try do that. He also has the recently submitted AE37 metabolite application, 14/865,862. AE37met is the directly-synthesized drug that the body metabolizes A2-73 into. Metabolic conversions are generally protected by the IP of the parent compound, and the ANAVEX PLUS patent covers the naturally-occurring metabolite...so I am, again, not sure what he is trying to accomplish. Further layers of protection, I guess.
I generally take it all to mean Dr V is trying to protect the compound from others, and not competing with Anavex. As Missling would say, "There is no dispute"!
Here are all of Dr V's apps:
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=vamvakides&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PG01
The whole A2-73 development is just a typical lead compund game played-out by baby bios with provacative pipelines, IMO. A3-71 will be our triumph, as it can do on it's own what PLUS cannot begin to accomplish. It is fully protected with a COM & MOU patent and ready for speedy development.
The ASS poster will be on display Thursday at 12:00PM Athens time, which is 5:00AM ET. We should see a PR between then and market open.
We will have to license A2-73 to stay alive. A3-71 is all ours, and not a penny will be relinquished!
§
What they said! The Published Documents tab has a View button that will bring up the actual app text.
Nothing new on PLUS, Anavex has until April 17 to respond to the Non-Final Rejection. Dr V's app, 14/395,581, got the Election Requirement recently.
§
Yes...5 days until we present in Greece and we're one of the few who don't have an abstract available. Hope it helps keep things mellow.
AAT: 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy
SPEAKERS 2016
Christopher U. Missling*
UPDATE ON ON-GOING PHASE 2A TRIAL OF NEW EXPLORATORY ALZHEIMER’S
DRUG ANAVEX 2-73
(Abstract not available at time of publication)
The other two are:
Suzanne Craft*
INSULIN THERAPY IN ALZHEIMER’S DISEASE: EVIDENCE OF CLINICAL EFFECT
(Abstract not available at time of publication)
Looks like PO results for SNIFF Study:
https://clinicaltrials.gov/ct2/show/NCT01767909
Headed up by Paul Aisen and USC
and
Lon Schneider*
THE BEST TREATMENT? ONE THAT WILL WORK
(Abstract not available at time of publication)
Dr Schneider is also from USC. I could not ascertain what he might be presenting on specifically.
I'm fine with the 3-71 poster:
"There is no cure for Alzheimer’s disease (AD), making it one of the largest unmet medical needs in
neurology. AF710B is a novel selective M1 muscarinic receptor allosteric agonist and sigma-1 receptor
agonist. In vitro, it rescues synaptic loss and reduces oxidative stress and apoptosis. In 3xTg-AD
mice, AF710B mitigated cognitive deficits and decreased AD-like hallmarks (e.g. BACE1, GSK3beta
activity, p25/CDK5, neuro-inflammation, Amyloid-beta, plaques and tau pathologies) [Fisher et
al, 2015 Neurodegener Dis. DOI:10.1159/000440864]. In a further extension, we tested whether
AF710B can reduce AD-like neuropathology and alleviate cognitive impairment in McGill-R-Thy1-
APP transgenic (tg) rats. Tg versus wild type (wt) rats of 12 months of age were orally treated with
either AF710B (10µg/kg) or vehicle (PBS) daily for 4.5 months. To establish whether AF710B may
hold true disease-modifying properties, we implemented a unique experimental design where the
treatment was interrupted for 5 weeks before submitting rats to behavioral tests designed to assess
cognition. Long-term chronic treatment with AF710B was capable of fully reverting the cognitive
deficits at later stages of the AD-like Amyloid-beta neuropathology in the McGill-R-Thy1-APP tg
rats, as evidenced by a complete reversal of the deficit measured by the Novel Object Recognition
and Morris Water Maze tasks. Importantly, this effect was maintained following a 5-week interruption
in the treatment, suggesting true disease-modifying properties of AF710B. An ELISA performed
on cortical samples showed a trend towards a decrease in Amyloid-beta 42 soluble and
insoluble fractions in treated tg rats, supporting a possible shift in the APP processing towards
a non-amyloidogenic pathway. Notably, McGill-R-Thy1-APP rats display overt signs of neuro-inflammation
making this model ideally suited to test AF710B on this aspect of the disease. With M1/
sigma-1 activity as well as putative disease-modifying properties at very low doses, AF710B is a
promising novel therapeutic agent for the treatment of AD."
Some A2-73 mouse model study data for Novel Object Recognition is here:
http://www.anavex.com/files/AAIC_Poster_Tangui_tau_July_2011.pdf
Some A2-73 mouse model study data for Morris Water Maze is here:
http://www.anavex.com/files/1311_Poster_Val_Def_final.pdf
Perhaps we'll be able to compare those charts with the A3-71 poster.
§
I'm sure you meant 4:10ET and, yes, the PR came then. I was commenting from the stated "traders had no time" standpoint. I was a trader and got the info from OTC before the market closed. If the retail investor feels disadvantaged, they can always become a trader if they want that added leverage.
I also knew iHub operates on ET before I knew how to do good DD
GLTA
§
They stated 12, 26 and 52 week marks. Obviously interim results for the trial type is not a good idea, I have expressed this personally to management. The co has already posted attendance at CSS in May. I think this is a further step in adding some order to the timeline of updates and that conference is safely within the 26 week time frame, so they planned it this far out.
One thing we can be sure of is if the trial results meet all those parameters unknown to us shareholders, the company will be progressing behind the scenes before we see the data. The goals expressed in the past have been squarely met, so when the company indicates it is moving ahead with a guided P2/3 it seems fairly safe to assume this will occur.
Some very big experts in the field who also lend their name to our SAB have been quoted saying very positive things about the compounds. Independently-funded studies and private grants are becoming apparent in AD and other indications.
The murky past is rarely an advantage to the intrepid investor. That cloud over this issue becomes thinner each day, as do the shares.
Dr Missling's employment agreement comes up for consideration in June, IIRC. The outcome and any associated milestones for the future could provide good clarity. Just as if we were back in 2013 discussing the likelihood of those first four misslingstones being achieved. That would be a place to see disclosure of future key intentions.
Thanks JB3729 for the link.
§
The daily list hit the terminal at 1:00ET. Whatever. I personally traded on the info before the market closed, that's all I can say. The post is gone, my opinion slightly changed. Good day.
§
Totally agree. The scheduled 12 week update comes first. I don't even think 26 week results for the whole cohort will be presented in May. Perhaps a partial set then.
We should be bracing for a round of funding, IMO. Lincoln Park did not destroy us with toxic financing the last round and the current deal structure does not favor that happening this time, either. The co has made clear the intention to partner P3 - commercialization. I believe an agreement based on verbal milestones has been in place for some time, and that is the reason we got such a favorable looking deal from LPC. Purely a standby instrument.
Dr Missling has all the connections he needs and knows exactly what terms must be met to get execution. The advances made by this company since his arrival show confidence in the pipeline and a diligent business plan. Successfully partnering the lead compound could be considered a given step, if all else falls into place.
-----------------------
On the A3-71 poster being presented, I think it is quite exciting.
From my reading, in short, the McGill rat was developed to express brain degradation as it ages that more successfully mimics human pathology than previous rat models have been able to do. The mouse models are different, they need good rat models.
http://www.ncbi.nlm.nih.gov/pubmed/20164597
The McGill rat was studied in depth and the conclusion:
"This study demonstrates that a considerable component of the intracellular AD-like pathology in McGill-Thy1-APP rats consists of Aß peptides. The intracellular material reflects a variety of molecular species, including free Aß, APP, CTFs as well as aggregated Aß peptides in the form of oligomers. Future investigations on this issue are warranted, particularly to examine which form of Aß predominates within neurons and in which compartment; as well as dissecting the differential contributions of intraneuronal species to the development and progression of CNS dysfunction. A similar pathological situation is likely to occur at the earliest, silent stages of AD progression in the human brain."
Full text here:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229908/
In this study it seems they used MRI scans to test for differences in brain volume between wild type (WT) and the genetically modified (TG) rats as they age.
My guess is in this forthcoming study they used that same methods to test for differences between the TG rats and those same who were administered A3-71.
One thing I find interesting is that McGill U. itself chose to test A3-71 on their prized specimens. Maybe just grasping at straws. I couldn't find anything recent on PsycoGenics and their use of the McGill rat.
A3-71 is our "super drug" IMO.
§
The BOD announced the 1:4 - 1:6 beforehand, and the split PR hit at 1:00(??...not at desk and net access here stinks or I'd find some links ). I remember there being ample time to decide what to do. The stock dropped on brief heavy volume but stabilized before market close.
Ha ha! I said to myself, you didn't check the glance schedule! Didn't want to venture further down speculation road. I see it remains the same. Very odd, as I thought to mention something along the lines of not having a title change of obvious nature like in Nov. Now they go and remove the entire slot on the one program, and clearly note the correct time on the one all the attendees will have in their hands.
I had hoped for none of these shenanigans this round. Dr Fisher is obviously acutely involved with the symposium and to make vague the presence of our company and those associated just adds fuel to the ill-willed fire, IMO. Oh well, the enigma is exciting, I suppose :)
I guess if the data is really that significant, regardless of parameters, and a fat P3 is announced, the stock could do that to da moon thingy...we shall see.
That is the study done by Dr Fisher et al in 2013 which he lectured about in 2014:
http://www.anavex.com/?news=anavex-3-71-highly-effective-and-disease-modifying-against-all-major-alzheimers-hallmarks-in-preclinical-disease-model
http://www.anavex.com/files/AbstractBook__WEB2014_2_Pages.pdf
http://www.anavex.com/pdf/2014-07-13_Fisher_Abstract_for_AAIC_meeting_2014.pdf
The data being presented next week is a study done at McGill U. last year...I believe?
33. Hélène Hall, M. Florencia Iulita, Adriana Ducatenzeiler, Abraham Fisher, A. Claudio Cuello
[Category: Pre-clinical Trials]
AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible diseasemodifying
properties in McGill-R-Thy1-APP rats
Went to check the program and notice the 12:20 - 12:40 slot for Anavex is not listed? WTF?
http://www.siumed.edu/cpd/alzheimer/program.html
"12:20 – 13:45 Lunch and informal networking with the experts"
The pdf program still has it listed:
http://www.siumed.edu/cpd/alzheimer/pdf/Program_2016.pdf
Xena: The run up was organic. I was there, trading every day. It was the 10MM naked shares used the week of Nov 9 that did the damage.
§
Update...plain vanilla to lessen speculation and avoid accusations of hyping would be my guess.
The lab, PsychoGenics, that just did the RETT Syndrome study has a liscense to the McGill-R-Thy1-APP rat, but it does not appear the one used in the RETT study.
Preclinical
Re5
Syndrome
8
Breeding
info
§? Female
mice
with
heterozygous
(HET)
MECP2--null
muta,on#
§? A
mouse
with
a
MECP2--null
muta,on
causes
neurological
symptoms
that
mimic
ReN
syndrome
§? Breeding
done
at
Jackson
Laboratories,
mice
provided
at
4--5
weeks
of
age
Sorry, stoopid pdf C&P...
Ok, enough lab rat conspiracies. Nice drop...stink bid time tom?
§
Here she is with the rest of the group:
http://www.medicine.mcgill.ca/pharma/cuellolab/labgroup.htm
Advanced AD rat model. This will be most interesting!
" The cognitive functions in transgenic McGill-R-Thy1-APP rats, as assessed using the Morris water maze task, were found already altered as early as at 3 months of age, when no CNS plaques are yet present. The spatial cognitive impairment becomes more prominent in older animals (13 months), where the behavioral performance of Tg rats positively correlates with the levels of soluble Abeta (trimers) measured in the cortex."
http://www.ncbi.nlm.nih.gov/pubmed/20164597
§
More interesting is it is listed on the Events page, but not in the Events box on the homepage. The poster will be on the preclinical A3-71 data presented by investigator Hall and displayed for the first two days. Dr Missling will give an oral update with slides on A2-73 P2a on Saturday. This is how I read it.
It seems the team publishing the A3-71 findings are from McGill U. Hélène Hall is from Lund U, coincidentally?
http://www.med.lu.se/expmed/brains/members/former_members/phd_students/helene_hall
https://www.researchgate.net/profile/M_Florencia_Iulita2
https://www.researchgate.net/profile/Adriana_Ducatenzeiler
http://www.medicine.mcgill.ca/pharma/cuellolab/cuello.htm
Alright then...Greece it is.
From the program:
Core Supporters
F. Hoffman-La Roche AG
Eli Lilly and Company
Supporters
AB Science
Alzheon Inc.
Anavex Life Sciences Corp.
Axon Neuroscience SE
Axovant Sciences Inc.
Biogen
The Lipididiet Consortium
Neurimmune
Otsuka-Lundbeck
Probiodrug AG
Stemedica International SA
TauRx Pharmaceuticals Ltd.
Worldwide Clinical Trials Inc.
International Scientific Advisory Committee
Karen Ashe, USA
Robert Becker, USA
Constantin Bouras, Switzerland
Luc Buée, France
Claudio Cuello, Canada
Bruno Dubois, France
Rodger Elble, USA
Abraham Fisher, Israel
Giovanni Frisoni, Switzerland
Serge Gauthier, Canada
Panteleimon Giannakopoulos, Switzerland
Christoph Hock, Switzerland
Khalid Iqbal, USA
Amos Korczyn, Israel
John Morris, USA
Roger Nitsch, Switzerland
Agneta Nordberg, Sweden
Giancarlo Pepeu, Italy
Philippe Robert, France
Lon Schneider, USA
Dennis Selkoe, USA
Bengt Winblad, Sweden
Manfred Windisch, Austria
Drs Missling and Fisher are listed as invited speakers, yet in a quick scan of the confirmed speakers on the website, it looks like they are the only two not listed.
The program states:
"Speakers’ abstracts and oral presentations from the 14th International Athens/Springfield Symposium on
Advances in Alzheimer Therapy have been published as a supplement in the on-line journal, Neurobiology
of Aging, Vol. 39 Issue S1, March, 2016.
This program book contains the index to poster abstracts from the 14th International Athens/Springfield
Symposium on Advances in Alzheimer Therapy. The text of the poster abstracts can be found by visiting
www.ad-springfield.com"
But the Poster Information link on the website is dead:
http://www.siumed.edu/cpd/alzheimer/general#poster.html
"The requested URL /cpd/alzheimer/general was not found on this server."
Watcha think about that scottsmith?
Oral presentation:
Saturday, March 12, 2016
Room: TERPSICHORE
12:20 – 12:40 Christopher U. Missling (New York, USA)
Update on on-going phase 2a trial of new exploratory Alzheimer’s
drug ANAVEX 2-73
(supported by Anavex Life Sciences Corp.)
Another critical data release on Saturday.
Posters
Posters will be mounted on Wednesday, March 9, beginning at 12:00. They will be displayed until Friday,
March 11, at 17:30.
33. Hélène Hall, M. Florencia Iulita, Adriana Ducatenzeiler, Abraham Fisher, A. Claudio Cuello
[Category: Pre-clinical Trials]
AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible diseasemodifying
properties in McGill-R-Thy1-APP rats
This will be Hélène Hall presenting A3-71 preclinical data.
Changes to the website intro. Used to say:
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s disease, other CNS diseases, and various types of cancer.
Now says:
Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer.
http://www.anavex.com/
New market relations personnel hard at work. How will they handle the upcoming media event?
GLTA
§
Certainly not!
Elliot Favus doesn’t like when I tweet about him. pic.twitter.com/DF1QPhxLUe
— Adam Feuerstein ✡️ (@adamfeuerstein) January 28, 2016
Pure speculation. I think he will be attending this conference and presenting the 12 week update in a poster at the Tuesday 12:20 - 1:10 LUNCH AND POSTER SESSION. He has been there the past several years. We shall see if we get a PR this week. There are many neuro conferences in March, like the Athens/Springfield Symposium, and apparently Dr Fisher is presenting on A3-71 there.
I believe the company is announcing attendance at critical data release conferences closer to the date in order to decrease hype and issues with the stock that detract from the scientific validity of the presentation.
At this point there can be no doubt that the 12 week results for the last participants enrolled in September are ready.
§
Yes, QUITE likely. We didn't need it on the whole the first two times. But we must remain intrepid investors and not count those eggs until they hatch.
georgejjl: Don't get all sentimental on us!
Just seeing something affect CNSDs on a physiological level is progress toward the goal. In vivo testing is our only hope.
Have a great weekend peeps! Back to work stuff next week until Easter, out of town...so if we rock it... good work!
BTA
§
Yes, you are correct. I think you are an astute investor too, and an asset to this board. It's a fun show to watch, an OTC getting it's just rewards. Best to you all.
Remember, there may be other "paid in shares" arrangements in place that could make all the recent O/S counts non-related to warrant conversions. Dr Missling's handling of the share count has been impeccable. We will need funding, though, for all of these new endeavors. Mid year will be an expected budget assessment for the 2017 FY. August will be the deadline for "how are we going to fund this stuff?".
Thank you for your share count service JBG!
§
Were you not drinking?
YES! We are trading like we are there again, which represents a stellar opportunity for those that missed the first leg. Start swinging it up to $8 and take your profits before it drops to the $5 level where a financing arrangement is likely to fall.
You can cover your investment and still be poised to take advantage of, possibly, the first S1/M* modulator to be brought to market. The science is valid...I speak from experience!
§
Because stocks hit highs and level-down, regardless of the future prospects. Many OTC stocks appear to be on the verge of busting out but do not deliver on their promises. OCLG. I'm just saying I could have easily amassed a 20 -30MM position in the mid .01s and given my DD I would have been selling for profit around .045. But it would take a few days of good volume to sell those shares. If this continues a strong upwards rally, and that includes some minor 2-3% down days, then that would indicate some strong belief that this is worth the expected sacrifice that will be necessary to put the company in the eyes of a suitor, or actual player in the space.
I would sell because I could increase my position playing the momentum. All this 10¢-to-the-moon talk is not what will send it there.
§
I agree with your statement, but the OP is correct in that there is less hype leading up to the data release. Trading more like June-July. My family buyers like that as they are swing-trading now and impressed with the incrementals. I'm just eating popcorn.
If the pattern holds the cabal will let it run up again on retail buying and try do do a 50%-er of what they did before. Perhaps around 8$ this time.
BeingReal: The vibe of people thinking similar things at the same time across the span...degrees of separation-type stuff, not necessarily the exact same idea, but same vibe. Sorry, too much LSD!
§
My son (12) has a learning account. He decided he likes SIAF and I said, "I did too son...I did too". Undaunted, he put in his bid for 1264 @ 7.90. He got filled today. He was rewarded with an after-hours PR. "See, I told ya so Dad!" was his response when he got home from school. All I could do was grin!
§
My boy is (trying to, lol!) swing trading this in his learning account. I am not in but have been setting up DD for him since November. If I was in I might have 20 - 30MM @ .014 and I would have been selling @ .045 for the past 4 days. It would have taken that long on this strong volume just to get rid of that many shares. I guarantee there are a few others not posting to this board who are doing just that. Consider it. Look at the volume back in Oct/Nov. Those shares WILL hit.
The company will announce the intent to return to reporting status and desire to seek an exchange listing. They will reduce the share count in the name of "attracting institutional investment", etc, etc.
Nice run for you peeps. I hope it does do 10¢, but also that my son get his .036s. Nice to see so many doing well!
§
See how that works?
If the subpoena had anything to do with impropriety by the co or officers, and the CEO felt he needed to cover his butt, then maybe yes, you would see some fluffy PRs. The subpoena is not material to the company's endeavors, do you get it? It's like there was a horsefly biting you and the other campers got mad because you didn't tell them about it, instead of continuing to cook the great BBQ they were about to have. Sheesh!....kabob!
§
And maybe he will. I really don't give a knockout mouse's ass so-long as he keeps doing all the other things he has been doing.
I hope he enjoys the beach down in Miami. He deserves it.
§